Skip to main content

Dosage and administration
How to determine dosage of Revonto for each patient
Dosage and Administration

As soon as the malignant hyperthermia reaction is recognized, all anesthetic agents should be discontinued; the administration of 100% oxygen is recommended. Revonto should be administered by continuous rapid intravenous push beginning at a minimum dose of 1 mg/kg, and continuing until symptoms subside or the maximum cumulative dose of 10 mg/kg has been reached.

If the physiologic and metabolic abnormalities reappear, the regimen may be repeated. It is important to note that administration of Revonto should be continuous until symptoms subside. The effective dose to reverse the crisis is directly dependent upon the individual’s degree of susceptibility to malignant hyperthermia, the amount and time of exposure to the triggering agent, and the time elapsed between onset of the crisis and initiation of treatment.

IV
Pediatric Dose:
Experience to date indicates that the dose of Revonto for pediatric patients is the same as for adults.

Dosing Chart

Weight of Patient Required Number of Revonto Vials
10 22 0.5 1 1.3 2 3 4 5
15 33 0.8 1.5 1.9 3 4.5 6 7.5
25 55 1.3 2.5 3.1 5 7.5 10 12.5
35 77 1.8 3.5 4.4 7 10.5 14 17.5
50 110 2.5 5 6.3 10 15 20 25
65 143 3.3 6.5 8.1 13 19.5 26 32.5
80 176 4 8 10 16 24 32 40
95 209 4.8 9.5 11.9 19 28.5 38 47.5
110 242 5.5 11 13.8 22 33 44 55
125 275 6.3 12.5 15.6 25 37.5 50 62.5
140 308 7 14 17.5 28 42 56 70
155 341 7.8 15.5 19.4 31 46.5 62 77.5
165 364 8.3 16.5 20.6 33 49.5 66 82.5
*2.5 mg/kg is the recommended prophylactic dose of Revonto. See below for additional information.

Preoperative Usage

Revonto and/or dantrolene sodium capsules may be administered preoperatively to patients judged malignant hyperthermia susceptible as part of the overall patient management to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia.

Initiaing Revonto
INITIATING REVONTO:
The recommended prophylactic dose of Revonto is 2.5 mg/kg, starting approximately 1.25 hours before anticipated anesthesia and infused over approximately 1 hour. This dose should prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia provided that the usual precautions, such as avoidance of established malignant hyperthermia triggering agents, are followed.
Additional Dosage
ADDITIONAL DOSAGE:
Additional Revonto may be indicated during anesthesia and surgery because of the appearance of early clinical and/or blood gas signs of malignant hyperthermia or because of prolonged surgery (see also CLINCAL PHARMACOLOGY, WARNINGS, and PRECAUTIONS). Additional doses must be individualized.
Oral Administration
ORAL ADMINISTRATION OF DANTROLENE SODIUM CAPSULES:
Administer 4 to 8 mg/kg/day of oral dantrolene sodium in three or four divided doses for 1 or 2 days prior to surgery, with the last dose being given with a minimum of water approximately 3 to 4 hours before scheduled surgery. Adjustment can usually be made within the recommended dosage range to avoid incapacitation (weakness, drowsiness, etc.) or excessive gastrointestinal irritation (nausea and/or vomiting). See also the package insert for dantrolene sodium capsules.

As soon as the malignant hyperthermia reaction is recognized, all anesthetic agents should be discontinued; the administration of 100% oxygen is recommended. Revonto should be administered by continuous rapid intravenous push beginning at a minimum dose of 1 mg/kg, and continuing until symptoms subside or the maximum cumulative dose of 10 mg/kg has been reached.

Post Crisis Follow-Up

Dantrolene sodium capsules, 4 to 8 mg/kg/day, in four divided doses should be administered for 1 to 3 days following a malignant hyperthermia crisis to prevent recurrence of the manifestations of malignant hyperthermia. Intravenous dantrolene sodium may be used postoperatively to prevent or attenuate the recurrence of signs of malignant hyperthermia when oral dantrolene sodium administration is not practical. The i.v. dose of dantrolene sodium in the postoperative period must be individualized, starting with 1 mg/kg or more as the clinical situation dictates.


Open ISI